for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Genomic Health, Inc.

GHDX.OQ

Latest Trade

70.97USD

Change

0.17(+0.24%)

Volume

541,836

Today's Range

70.50

 - 

71.38

52 Week Range

50.85

 - 

91.03

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
70.80
Open
70.80
Volume
541,836
3M AVG Volume
14.37
Today's High
71.38
Today's Low
70.50
52 Week High
91.03
52 Week Low
50.85
Shares Out (MIL)
37.29
Market Cap (MIL)
2,646.40
Forward P/E
47.85
Dividend (Yield %)
--

Next Event

Q3 2019 Genomic Health Inc Earnings Release

Latest Developments

More

Genomic Health Reports Q2 EPS $0.42

Exact Sciences In Advanced Talks To Buy Genomic Health For About $2.8 Bln- Bloomberg

Genomic Health Says German Federal Joint Committee Issues Positive Reimbursement Decision For Oncotype DX Breast Recurrence Score Test

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Genomic Health, Inc.

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

Industry

Healthcare Facilities

Contact Info

301 Penobscot Dr

+1.650.5569300

http://www.genomichealth.com/

Executive Leadership

Kimberly J. Popovits

Chairman of the Board, President, Chief Executive Officer

Gordon Bradley Cole

Chief Financial Officer

Frederic Pla

Chief Operating Officer

Steven Shak

Chief Scientific Officer

Laura Leber Kammeyer

Chief Communications Officer

Key Stats

3.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.3K

2017

0.3K

2018

0.4K

2019(E)

0.4K
EPS (USD)

2016

-0.420

2017

0.010

2018

1.060

2019(E)

1.486
Price To Earnings (TTM)
53.96
Price To Sales (TTM)
6.17
Price To Book (MRQ)
8.34
Price To Cash Flow (TTM)
41.56
Total Debt To Equity (MRQ)
0.11
LT Debt To Equity (MRQ)
0.05
Return on Investment (TTM)
16.88
Return on Equity (TTM)
14.59

Latest News

Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal

Exact Sciences Corp <EXAS.O> said on Monday it will buy peer Genomic Health Inc <GHDX.O> for about $2.8 billion in cash and stock, expanding the cancer diagnostic company's testing capabilities to breast and prostate cancers.

Exact Sciences to buy Genomic Health for $2.8 billion

Cancer diagnostics company Exact Sciences Corp said on Monday it will buy healthcare company Genomic Health Inc for about $2.8 billion to bolster its cancer testing business.

Exact Sciences in advanced talks to buy Genomic Health for $2.8 billion: Bloomberg

Cancer diagnostics company Exact Sciences Corp <EXAS.O> is in advanced negotiations to buy healthcare company Genomic Health Inc <GHDX.O> for about $2.8 billion to strengthen its cancer testing, Bloomberg reported on Saturday.

BRIEF-New Data Reinforce Positive Impact Of The Oncotype Dx Genomic Prostate Score Test In Guiding Treatment Decisions

* NEW DATA REINFORCE POSITIVE IMPACT OF THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST IN GUIDING TREATMENT DECISIONS Source text for Eikon: Further company coverage:

BRIEF-Genomic Health Q1 Loss Per Share $0.11

* GENOMIC HEALTH ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND REPORTS RECENT BUSINESS PROGRESS

BRIEF-Tailorx Results Aid In Assessing The Effect Of Chemotherapy In Women With Early-Stage Breast Cancer And Oncotype Dx Breast Recurrence Score Results Of 11 To 25

* LANDMARK TAILORX RESULTS AID IN ASSESSING THE EFFECT OF CHEMOTHERAPY IN WOMEN WITH EARLY-STAGE BREAST CANCER AND ONCOTYPE DX BREAST RECURRENCE SCORE® RESULTS OF 11 TO 25

BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05

* GENOMIC HEALTH ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK

BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05

* GENOMIC HEALTH ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK

BRIEF-Genomic Health Expands Offering To Prostate Cancer Patients With Launch Of Oncotype DX AR-V7 Nucleus Detect Test To Predict Treatment Response In Metastatic Disease

* GENOMIC HEALTH EXPANDS OFFERING TO PROSTATE CANCER PATIENTS WITH LAUNCH OF ONCOTYPE DX® AR-V7 NUCLEUS DETECT™ TEST TO PREDICT TREATMENT RESPONSE IN METASTATIC DISEASE Source text for Eikon: Further company coverage:

BRIEF-Genomic Health - Oncotype DX Genomic Prostate Score™ Test Increases Use Of Active Surveillance

* ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST INCREASES USE OF ACTIVE SURVEILLANCE BY 30 PERCENT IN LOW-RISK PATIENTS, RESULTING IN GREATER ADHERENCE TO GUIDELINE-BASED CARE Source text for Eikon: Further company coverage:

BRIEF-Genomic Health Announces Research Collaboration with Janssen Pharma

* GENOMIC HEALTH ANNOUNCES RESEARCH COLLABORATION WITH JANSSEN PHARMACEUTICALS TO EVALUATE THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST FOR POTENTIAL DRUG DEVELOPMENT

BRIEF-Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests

* GENOMIC HEALTH AND CLEVELAND DIAGNOSTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE NEW PROSTATE CANCER TESTS

BRIEF-Genomic Health Q3 loss per share $0.06

* Genomic Health announces third quarter 2017 financial results and reports recent business progress

BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test

* GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS

BRIEF-Palmetto GBA issues positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test

* Palmetto GBA issued positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test Source text for Eikon: Further company coverage:

BRIEF-Genomic Health Q2 loss per share $0.08

* Genomic Health announces second quarter 2017 financial results and reports recent business progress

BRIEF-Genomic Health Q1 revenue $84 million

* Genomic Health announces first quarter 2017 financial results and reports recent business progress

BRIEF-Genomic Health Q4 EPS $0.04

* Genomic health announces 2016 fourth quarter and year-end financial results, provides 2017 financial outlook

BRIEF-Genomic Health Q3 loss per share $0.08

* Genomic Health reports third consecutive quarter of double-digit revenue growth in announcement of third quarter 2016 financial results

BRIEF-Genomic Health reports positive topline clinical validation study results

* Genomic Health announces positive topline clinical validation study results demonstrating Oncotype DX prostate cancer test predicts risk of metastasis and mortality Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up